01 January 2002
Assessment of iron metabolism in children with chronic hepatitis B - prognostic factor in interferon alpha therapy.
Agnieszka Monika Chrobot, Andrzej Chrobot, Anna Szaflarska-SzczepanikMed Sci Monit 2002; 8(4): CR269-273 :: ID: 420869
Abstract
BACKGROUND: The aim of the study was to assess iron metabolism in childrenwith chronic hepatitis B and to establish whether it had any influence on the results of interferon alphatherapy. MATERIAL/METHODS: The study was carried out in a group of 38 children aged from 2 to 16 yearswith chronic hepatitis B diagnosed according to serological, biochemical and histopathological criteria.All the patients were treated according to the commonly adopted schedule: interferon alpha administeredsubcutaneously three times a week at 3 MIU doses for 20 weeks. During the therapy and one-year follow-upafter its completion, biochemical liver function parameters, serological HBV markers, and iron and ferritinlevels were monitored. RESULTS: The therapy resulted in obtaining seroconversion in the HBe system in9 patients (23.68%). Liver bioptates in that group of patients demonstrated more advanced changes dueto inflammatory activity and fibrosis processes, significantly higher values of alanine aminotransferase,lower serum levels of iron and ferritin with more pronounced difference in ferritin levels, althoughthe differences reached no statistical significance. CONCLUSIONS: No disturbances of iron metabolismwere observed in children with chronic hepatitis B. In the group of patients with detectable seroconversionin the Hbe system resulting from interferon alpha therapy, lower serum levels of iron and ferritin wereobserved. Routine determinations of serum iron and ferritin levels as a prognostic factor for positiveresponse to interferon alpha seem to be of little use, especially in children, in whom no iron accumulationin liver tissue is observed in histopathological assessment of liver bioptates
Keywords: Adolescent, Alanine Transaminase, Antiviral Agents, Child, Child, Preschool, ferritin, Follow-Up Studies, Hepatitis B Antibodies, Hepatitis B e Antigens, Hepatitis B, Chronic, Interferon-alpha, Iron, Liver Cirrhosis
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952